Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 9/20 | 0.50 |
| ▸ | CA2 | P00918 | 9/20 | 0.50 |
| ▸ | CA12 | O43570 | 6/20 | 0.50 |
| ▸ | CA9 | Q16790 | 6/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2247530 | 1.00 | MEN1 (0.56) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL8171267 | 1.00 | MEN1 (0.56) | MEN1KMT2AGAATDP1MAOA | |
| Hydrochloric Acid SCHEMBL16486989 | 0.98 | MEN1 (0.55) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL12215023 | 0.98 | TDP1 (0.58) | MEN1KMT2AGAATDP1MAOA | |
| Hydrochloric Acid SCHEMBL7352392 | 0.98 | MEN1 (0.55) | MEN1KMT2AGAATDP1MAOA | |
| Hydrochloric Acid SCHEMBL138401 | 0.98 | MEN1 (0.55) | MEN1KMT2AGAATDP1MAOA | |
| Hydrochloric Acid SCHEMBL30018358 | 0.97 | TDP1 (0.56) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL2855685 | 0.95 | MEN1 (0.62) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL131062 | 0.95 | MEN1 (0.62) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL2855689 | 0.95 | MEN1 (0.62) | MEN1KMT2AGAATDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 347 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382202-B2 | Precursor for labeling therapeutic agent for liver cancer and method for manufacturing the same | Atomic Energy Council—Institute of Nuclear Energy Research (TW) | 2016-07-05 | — | — | US | claimed |
| US-20150322005-A1 | PRECURSOR FOR LABELING THERAPEUTIC AGENT FOR LIVER CANCER AND METHOD FOR MANUFACTURING THE SAME | ATOMIC ENERGY COUNCIL-INSTITUTE OF NUCLEAR ENERGY RESEARCH (TW) | 2015-11-12 | — | — | US | claimed |
| EP-3710458-B1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12551570-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2026-02-17 | — | — | US | disclosed |
| US-12479927-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2025-11-25 | — | — | US | disclosed |
| US-20250312514-A1 | COACERVATE HYALURONAN HYDROGELS FOR DERMAL FILLER APPLICATIONS | ALLERGAN INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250270162-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | LIGHTHOUSE PHARMACEUTICALS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250177582-A1 | HIGH-AFFINITY LIGANDS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2025-06-05 | — | — | US | disclosed |
| CN-120077136-A | SiRNA and drug for inhibiting Amyloid Precursor Protein (APP) gene expression and application thereof | 广州必贝特医药股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-12312370-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-6211235-B1 | ALZHEIMERS DISEASE | ELAN PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | disclosed |
| US-6207710-B1 | FOR THERAPY OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. | 2001-03-27 | — | — | US | disclosed |
| US-6191166-B1 | ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. | 2001-02-20 | — | — | US | disclosed |
| EP-0942924-A2 | METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 1999-09-22 | — | — | EP | disclosed |
| US-5877030-A | REACTING AMINO ACID MOLECULES WITH REACTIVE XANTHENE DERIVATIVES, COMBINATORIAL LIBRARIES | SILICON VALLEY BANK | 1999-03-02 | — | — | US | disclosed |
| WO-1998022494-A9 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | — | 1998-08-20 | — | — | WO | disclosed |
| WO-1998022494-A2 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
| US-4341758-A | Immunochemical assay reagent for the determination of haptens, and assay method therewith | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1982-07-27 | — | — | US | disclosed |
| EP-0010405-A1 | Stable immunochemical assay reagent for the determination of haptens, and assay method using said reagent | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1980-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1G | MEN1 4045/4885KMT2A 3783/4885GAA 2003/4885 |
| US-12551570-B2 | Compounds comprising cleavable linker and uses thereof | FCGR2A, FCGR3B, FCGR1A | MEN1 3990/4885KMT2A 3562/4885GAA 1454/4885 |
| US-12312370-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | MEN1 3171/4885KMT2A 1002/4885GAA 164/4885 |
| US-20150322005-A1 | PRECURSOR FOR LABELING THERAPEUTIC AGENT FOR LIVER CANCER AND METHOD FOR MANUFACTURING THE SAME | FABP1, LIPC, HCCS | MEN1 542/4885KMT2A 3357/4885GAA 1201/4885 |
| US-20250312514-A1 | COACERVATE HYALURONAN HYDROGELS FOR DERMAL FILLER APPLICATIONS | CD44, CHIT1, CHIA | MEN1 3259/4885KMT2A 4110/4885GAA 357/4885 |
| US-12479927-B2 | Compounds comprising cleavable linker and uses thereof | VIP, ANTXR2, TNFRSF9 | MEN1 3064/4885KMT2A 3544/4885GAA 364/4885 |
| US-20250270162-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | MEN1 1912/4885KMT2A 300/4885GAA 74/4885 |
| US-20250177582-A1 | HIGH-AFFINITY LIGANDS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED DELIVERY APPLICATIONS | FAP, FIBP, FGFR1 | MEN1 3770/4885KMT2A 4220/4885GAA 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.